Pharmacokinetics and Bioavailability of Fluconazole in 2 Groups of Males with Human-Immunodeficiency-Virus (hiv) Infection Compared with Those in a Group of Males Without Hiv-Infection

Tett, S, Moore, S and Ray, J (1995) Pharmacokinetics and Bioavailability of Fluconazole in 2 Groups of Males with Human-Immunodeficiency-Virus (hiv) Infection Compared with Those in a Group of Males Without Hiv-Infection. Antimicrobial Agents and Chemotherapy, 39 8: 1835-1841.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ249199_OA.pdf Full text (open access) application/pdf 257.55KB 0
Author Tett, S
Moore, S
Ray, J
Title Pharmacokinetics and Bioavailability of Fluconazole in 2 Groups of Males with Human-Immunodeficiency-Virus (hiv) Infection Compared with Those in a Group of Males Without Hiv-Infection
Journal name Antimicrobial Agents and Chemotherapy   Check publisher's open access policy
ISSN 0066-4804
Publication date 1995-08-01
Year available 1995
Sub-type Article (original research)
Open Access Status File (Publisher version)
Volume 39
Issue 8
Start page 1835
End page 1841
Total pages 7
Place of publication WASHINGTON
Publisher AMER SOC MICROBIOLOGY
Language eng
Abstract Fluconazole pharmacokinetics, including absolute bioavailability, were determined for one group of controls (n = 10) and two groups of people with human immunodeficiency virus (HIV infection (those with CD4(+) T-cell counts of less than [n = 4] or greater than [n = 9] 200 cells per mm(3)). Twenty subjects received four doses of fluconazole; three doses were oral (50, 100, and 400 mg), and one dose was intravenous (either 50, 100, or 400 mg). The other three subjects received one or two doses. The groups were comparable in terms of the weight, body mass index, and estimated creatinine clearance of the subjects, but the people with HIV infection were older. Pharmacokinetic parameters indicated linearity in all subjects; the area under the plasma concentration-time curve and the maximum concentration increased in proportion to the dose. The fraction of an oral dose of fluconazole absorbed approximated unity in all three groups of subjects. The mean (+/- standard deviation) plasma clearance of fluconazole was lowest in the group of subjects with low CD4(+) T-cell counts; the value for this group was 0.74 +/- 0.19 liter/h, compared with 0.97 +/- 0.19 liter/h in the group with HIV infection and CD4(+) T-cell counts of greater than 200 cells/mm(3) and 1.18 a 0.23 liter/h in the group of control subjects (P < 0.05). The volume of distribution was lower in those with HIV infection (P = 0.04, corrected for weight). The half-life was longest in people with HIV infection and low CD4(+) T-cell counts (P = 0.01). This study has shown that some differences do exist between the pharmacokinetics of fluconazole in people with HIV infection and those in noninfected controls.
Keyword Clinical Pharmacokinetics
Fungal-Infections
Aids
Ketoconazole
Volunteers
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: ResearcherID Downloads - Archived
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 34 times in Thomson Reuters Web of Science Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 10 Sep 2011, 07:06:34 EST by System User on behalf of Scholarly Communication and Digitisation Service